GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Price-to-Owner-Earnings

Astellas Pharma (TSE:4503) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 1949. Start your Free Trial

As of today (2024-04-18), Astellas Pharma's share price is 円1465.50. Astellas Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Astellas Pharma's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Astellas Pharma was 209.06. The lowest was 10.51. And the median was 23.54.


TSE:4503's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 26.9
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-18), Astellas Pharma's share price is 円1465.50. Astellas Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.36. Therefore, Astellas Pharma's PE Ratio for today is 4,070.83.

As of today (2024-04-18), Astellas Pharma's share price is 円1465.50. Astellas Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was 円-3.80. Therefore, Astellas Pharma's PE Ratio without NRI for today is At Loss.

During the past 13 years, Astellas Pharma's highest PE Ratio without NRI was 137.00. The lowest was 0.00. And the median was 19.82.


Astellas Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Astellas Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.24 19.31 28.56 23.04 29.69

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.54 29.69 39.45 213.59 -

Competitive Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Price-to-Owner-Earnings falls into.



Astellas Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Astellas Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1465.50/-0.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (TSE:4503) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Astellas Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (TSE:4503) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (TSE:4503) Headlines

No Headlines